Curated News:

NEJM

Add to Favorites Subscribe Share
fbshare-NEJM

Showing results

110 of 326
hms-logo.gif
  • Embargo expired:
    17-Jul-2019 5:00 PM EDT

Article ID: 715716

Sustainable Savings on Medical Care

Harvard Medical School

Over eight years, patients covered under a global budget payment model for doctors and hospitals showed slower spending growth and better quality than comparable populations mostly under the traditional fee-for-service model.

Released:
12-Jul-2019 11:05 AM EDT
einstein-monte-logo-cmyk.jpg
  • Embargo expired:
    10-Jul-2019 5:00 PM EDT

Article ID: 715368

Novel Therapy for Acute Migraine Shows Promise in Phase 3 Clinical Trial

Albert Einstein College of Medicine and Montefiore Health System

A drug belonging to a new generation of acute migraine headache treatments was found to eliminate pain and reduce bothersome symptoms for people with migraine in a large-scale trial reported in the July 11 issue of The New England Journal of Medicine. The drug, rimegepant, is awaiting U.S. Food and Drug Administration approval and may offer advantages over currently available migraine medications. The study was led by researchers at Albert Einstein College of Medicine and Montefiore Health System.

Released:
5-Jul-2019 12:40 PM EDT
CUIMC_RGB.jpg
  • Embargo expired:
    26-Jun-2019 5:00 PM EDT

Article ID: 714754

Hidden Consciousness Detectable with EEG Just Days after Brain Injury

Columbia University Irving Medical Center

Nearly 1 in 7 brain-injured patients show early evidence of hidden consciousness—as revealed by EEG analysis—and are more likely to recover, researchers at Columbia have found.

Released:
21-Jun-2019 2:05 PM EDT

Channels:

All Journal News, Neuro, NEJM

Languages:

English

CCHMCLogo.jpg

Article ID: 714441

3 Signs of Progress Against Sickle Cell Disease

Cincinnati Children's Hospital Medical Center

June 19 is World Sickle Cell Awareness Day. Scientists at Cincinnati Children's have recently made three important steps forward in helping people with sickle cell in the U.S. and in sub-Saharan Africa live longer, better lives.

Released:
19-Jun-2019 8:05 AM EDT
Newswise: Study Shows Experimental Drug Can Encourage Bone Growth in Children with Dwarfism

Article ID: 714497

Study Shows Experimental Drug Can Encourage Bone Growth in Children with Dwarfism

Johns Hopkins Medicine

Researchers at Johns Hopkins Medicine, the Murdoch Children’s Research Institute in Australia and seven other medical institutions report that an experimental drug called vosoritide, which interferes with certain proteins that block bone growth, allowed the average annual growth rate to increase in a study of 35 children and teenagers with achondroplasia, a form of dwarfism. The patients’ average boost in height to about 6 centimeters (2.4 inches) per year is close to growth rates among children of average stature, and the side effects of the drug were mostly mild, according to the researchers.

Released:
18-Jun-2019 10:00 AM EDT

Article ID: 714147

Study Drug Delays Type 1 Diabetes in High Risk Children and Adults

Vanderbilt University Medical Center

A drug that targets the immune system can delay the onset of type 1 diabetes an average of two years in children and adults at high risk, according to findings from TrialNet’s Teplizumab (anti-CD3) Prevention Study published in the New England Journal of Medicine.

Released:
10-Jun-2019 9:45 AM EDT
Newswise: How to Improve Care for Patients with Disabilities? We Need More Providers Like Them

Article ID: 714077

How to Improve Care for Patients with Disabilities? We Need More Providers Like Them

Johns Hopkins Medicine

It is common for patients to prefer seeking care from a clinician similar to them — such as of the same gender, ethnicity and culture — who can relate to their experiences and make treatment plans that work better for their lives. To meet these preferences from patients and improve quality of care, a diverse clinician workforce that matches the diversity in the general population is needed. However, when it comes to patients with disabilities, the chance of getting a clinician “like them” is extremely low, which may lead to patients’ reluctance to seek care or follow prescribed interventions and treatments. Meanwhile, without adequate scientists with disabilities bringing perspectives to patient-centered research, the ability to improve care for patients with disabilities is limited.

Released:
10-Jun-2019 8:00 AM EDT
New Logo.png

Article ID: 713819

POLO trial for advanced pancreatic cancer: a new standard of care

University of Chicago Medical Center

Treatment with the drug olaparib significantly reduced the risk of disease progression or death from metastatic pancreatic cancer, according to findings from the recently completed, international, phase-III POLO (Pancreas cancer OLaparib Ongoing) trial.

Released:
3-Jun-2019 11:05 AM EDT
  • Embargo expired:
    2-Jun-2019 7:30 AM EDT

Article ID: 713589

Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer

Dana-Farber Cancer Institute

Enzalutamide, an oral androgen receptor inhibitor, can improve outcomes for men with metastatic hormone-sensitive prostate cancer (mHSPC), according to a large study presented by Christopher Sweeney, MBBS of Dana-Farber Cancer Institute's Lank Center for Genitourinary Oncology, during the American Society of Clinical Oncology (ASCO) Annual Meeting.

Released:
2-Jun-2019 6:30 AM EDT
Newswise: Adding ribociclib to hormone therapy extends lives of women with most common metastatic breast cancer
  • Embargo expired:
    1-Jun-2019 7:30 AM EDT

Article ID: 713647

Adding ribociclib to hormone therapy extends lives of women with most common metastatic breast cancer

University of California, Los Angeles (UCLA), Health Sciences

A UCLA-led study has found that using a drug called ribociclib in combination with a common hormone therapy may help premenopausal women with the most common type of breast cancer live longer than if they only receive the hormone therapy.

Released:
1-Jun-2019 7:30 AM EDT

Showing results

110 of 326

Chat now!